跳过至主要内容
返回讨论

根据最近的研究发现，我们如何能改进鳞状NSCLC患者的治疗选择？

Healthcare
全球
开始于 April 11, 2026

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (NSCLC). However, PD-L1-based subgroup results reveal a critical stratification signal. In patients with PD-L1 tumour proportion score (TPS) of under 50%, dual blockade achieved marked benefit (hazard ratio [HR] 0·63; 95% CI 0·41–0·98), whereas in patients with PD-L1 TPS of 50% or over, the improvement was numerical but not significant (HR 0·71; 0·37–1·33)

来源文章

添加陈述 分析 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
3 条陈述待投票 • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 3/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM 发布者 will • Apr 11, 2026
HARMONi-6试验的结果引发了关于我们对肺癌生物标志物现有认识的重要问题。我们需要讨论PD-L1 TPS是否应该成为治疗决策的主要决定因素，或者是否还应该考虑其他因素。
AI 翻译 · 显示原文

The results of the HARMONi-6 trial raise important questions about our current understanding of biomarkers in NSCLC. We need to discuss whether PD-L1 TPS should be the primary determinant in treatment decisions or if other factors should also be considered.

Vote options for this statement: agree, disagree, or unsure
💬 查看讨论
Be first to respond
Vote to see results
CLAIM 发布者 will • Apr 11, 2026
我们应该探索HARMONi-6试验的研究发现如何能够整合到现有的鳞状细胞肺癌治疗框架中。这包括考虑患者人口统计学特征和健康状况如何影响治疗效果。
AI 翻译 · 显示原文

We should explore how the insights from the HARMONi-6 trial can be integrated into existing treatment frameworks for squamous NSCLC. This includes considering how patient demographics and health characteristics influence treatment effectiveness.

Vote options for this statement: agree, disagree, or unsure
💬 查看讨论
Be first to respond
Vote to see results
CLAIM 发布者 will • Apr 11, 2026
尽管HARMONi-6试验显示出前景，但仅依赖PD-L1 TPS来制定治疗策略可能会过度简化鳞状细胞肺癌的复杂性。我们必须确保临床指南不会过早偏向某一种治疗方法，因为患者个体的治疗反应可能差异很大。
AI 翻译 · 显示原文

While the HARMONi-6 trial shows promise, relying solely on PD-L1 TPS for treatment strategies could oversimplify the complexities of squamous NSCLC. We must ensure that clinical guidelines do not prematurely favor one treatment over another, as individual patient responses can vary widely.

Vote options for this statement: agree, disagree, or unsure
💬 查看讨论
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us